EMA Invites Public Feedback on New PRIME Program
The PRIME program is a drug development scheme to enable accelerated assessment of medications for conditions with unmet need.
The European Medicines Agency (EMA) announced on Oct. 26, 2015 that it now welcomes public consultation on its PRIME program, which seeks to provide enhanced regulatory support for drugs in development that meet unmet medical need. EMA invited comments on the program until Dec. 23, 2015, and the agency published a reflection paper alongside the announcement “outlining the proposed eligibility criteria, procedure, key features, and data requirements for PRIME,” according to the EMA press release.
The launch of PRIME is slated for the first quarter of 2016. PRIME has been likened to FDA’s accelerated approval programs-such as its Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track designations-which help fast-track drugs through the regulatory process that appear to have a significant impact on public health.
A medication’s “significant impact” will be measured by the same evaluation standards as those not receiving PRIME support; however, the program will monitor those medications that demonstrate significant evidence of efficacy in clinical trials. The PRIME program will also provide sponsors with preliminary development guidance and will offer enhanced scientific advice during key development milestones. Additionally, another goal of the program goal is to strengthen clinical trial design to tease out more relevant patient information and data that would eventually aid a sponsor in getting market authorization for its drug.
The architects of PRIME believe that the program will particularly compel sponsors from academia. Through PRIME, researchers in these settings would be able to take advantage of the fee incentives that are offered to researchers with convincing nonclinical and tolerability data from preliminary trials and animal studies.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
